MXPA04001118A - Combinaciones antineoplasicas. - Google Patents

Combinaciones antineoplasicas.

Info

Publication number
MXPA04001118A
MXPA04001118A MXPA04001118A MXPA04001118A MXPA04001118A MX PA04001118 A MXPA04001118 A MX PA04001118A MX PA04001118 A MXPA04001118 A MX PA04001118A MX PA04001118 A MXPA04001118 A MX PA04001118A MX PA04001118 A MXPA04001118 A MX PA04001118A
Authority
MX
Mexico
Prior art keywords
antineoplastic combinations
antineoplastic
combinations
ekb
cci
Prior art date
Application number
MXPA04001118A
Other languages
English (en)
Inventor
J Gibbons James Jr
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA04001118A publication Critical patent/MXPA04001118A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated

Abstract

La presente invencion proporciona el uso de una combinacion de CCI-779 y EKB-569 en el tratamiento de neoplasmas.
MXPA04001118A 2001-08-07 2002-08-06 Combinaciones antineoplasicas. MXPA04001118A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31064601P 2001-08-07 2001-08-07
PCT/US2002/024841 WO2003020266A1 (en) 2001-08-07 2002-08-06 Antineoplastic combinations

Publications (1)

Publication Number Publication Date
MXPA04001118A true MXPA04001118A (es) 2004-05-20

Family

ID=23203475

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001118A MXPA04001118A (es) 2001-08-07 2002-08-06 Combinaciones antineoplasicas.

Country Status (27)

Country Link
US (4) US6617333B2 (es)
EP (2) EP1671943A1 (es)
JP (2) JP2005505549A (es)
KR (1) KR20040029406A (es)
CN (3) CN100415753C (es)
AR (2) AR036250A1 (es)
AT (1) ATE314069T1 (es)
AU (2) AU2002330994B2 (es)
BR (1) BR0211769A (es)
CA (1) CA2455126A1 (es)
CY (1) CY1104983T1 (es)
DE (1) DE60208385T2 (es)
DK (1) DK1414438T3 (es)
EA (2) EA011098B1 (es)
ES (1) ES2252512T3 (es)
HK (1) HK1061204A1 (es)
HU (1) HUP0401089A3 (es)
IL (2) IL159859A0 (es)
MX (1) MXPA04001118A (es)
NO (2) NO325503B1 (es)
NZ (3) NZ542272A (es)
PL (1) PL368303A1 (es)
SG (1) SG170612A1 (es)
TW (2) TWI305527B (es)
UA (1) UA77200C2 (es)
WO (1) WO2003020266A1 (es)
ZA (1) ZA200401801B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US20060199811A1 (en) * 1997-07-31 2006-09-07 Pfirrmann Rolf W Method of treatment for preventing or reducing tumor growth in the liver of patient
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
CN104116738A (zh) 2001-02-19 2014-10-29 诺华股份有限公司 癌症的治疗
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
JP4814520B2 (ja) * 2002-05-15 2011-11-16 エンドサイト，インコーポレイテッド ビタミン−マイトマイシン結合体
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
CL2004000016A1 (es) * 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
TWI405573B (zh) 2003-01-27 2013-08-21 Endocyte Inc 維生素-受體結合性藥物輸送共軛物中間物及製備方法
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
PT1615640E (pt) * 2003-04-22 2007-04-30 Wyeth Corp Combinações antineoplásticas
RU2006106267A (ru) * 2003-08-01 2006-07-27 Уайт Холдингз Корпорейшн (Us) Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
ATE383859T1 (de) * 2004-01-08 2008-02-15 Wyeth Corp Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
GT200500008A (es) * 2004-01-16 2005-08-16 Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
CA2585840A1 (en) * 2004-10-28 2006-05-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
CN113952459A (zh) * 2005-02-03 2022-01-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
AU2006222500B2 (en) * 2005-03-07 2011-09-01 Robarts Research Institute Use of a combination of Myxoma virus and rapamycin for therapeutic treatment
CN101175757B (zh) * 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
AU2006249598A1 (en) * 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
TW200716557A (en) * 2005-05-25 2007-05-01 Wyeth Corp Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
CA2608589A1 (en) * 2005-05-25 2006-11-30 Wyeth Methods of synthesizing 6-alkylaminoquinoline derivatives
WO2007001839A2 (en) * 2005-06-24 2007-01-04 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
CN101248047A (zh) * 2005-07-01 2008-08-20 惠氏公司 4-[(2,4-二氯-5-甲氧基苯基)氨基]-6-甲氧基-7-[3-(4-甲基-1-哌嗪基)丙氧基]-3-喹啉甲腈的晶型及其制备方法
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
JP5475992B2 (ja) * 2005-08-19 2014-04-16 エンドサイト，インコーポレイテッド 多剤リガンド結合体
AU2016259316B2 (en) * 2005-11-04 2018-09-06 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272
AU2013204788B2 (en) * 2005-11-04 2016-12-08 Wyeth Llc Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CA2933875C (en) * 2005-11-21 2018-06-26 Novartis Ag 40-o-(2-hydroxyethyl)-rapamycin for use as a sole drug substance in the treatment of carcinoid tumors arising from the foregut, midgut, or hindgut
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
WO2008121467A2 (en) * 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
EP2489372A3 (en) * 2007-03-14 2013-01-02 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
CA2690943A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
JP2011500835A (ja) 2007-10-25 2011-01-06 エンドサイト，インコーポレイテッド チューブリシン類および調製プロセス
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
SG191676A1 (en) 2008-06-17 2013-07-31 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
PT2326329T (pt) 2008-08-04 2017-02-14 Wyeth Llc Combinações antineoplásicas de 4-anilino-3-cianoquinolinas e capecitabina
JP2012510489A (ja) * 2008-12-02 2012-05-10 バイオコンパティブルズ ユーケー リミテッド 膵がんの治療
KR20190128004A (ko) 2009-04-06 2019-11-13 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
EP2621903B1 (en) 2010-09-29 2017-03-01 Intervet International B.V. N-heteroaryl compounds
PL2621923T3 (pl) 2010-09-29 2017-08-31 Intervet International B.V. Związki n-heteroarylu z mostkami cyklicznymi do leczenia chorób pasożytniczych
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
WO2014062697A2 (en) 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
US10274503B2 (en) 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
US9242965B2 (en) * 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2017111076A1 (ja) 2015-12-24 2017-06-29 協和発酵キリン株式会社 α、β不飽和アミド化合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU415255A1 (ru) * 1972-03-20 1974-02-15 Т. А. Асонова, А. Я. Берлин, А. Б. Зезин, Е. Ф. Разводовский СПОСОБ ПОЛУЧЕНИЯ р-БЕТАИ1ЮВВПТВci)iia aiisn^pii
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4194050A (en) 1976-04-30 1980-03-18 Sumitomo Chemical Company, Limited Process for producing an enamide
US4195021A (en) 1977-10-26 1980-03-25 Eli Lilly And Company 1,3-Disubstituted 2-azetidinone antibitotics
US4193983A (en) 1978-05-16 1980-03-18 Syva Company Labeled liposome particle compositions and immunoassays therewith
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5066493A (en) 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
BE897134A (fr) 1983-06-24 1983-12-27 Solvay Dienes polysubstitues
US4478959A (en) 1983-09-29 1984-10-23 Air Products And Chemicals, Inc. Amino and amido divalent metal carboxylates useful as catalysts for polyurethane formulations
DE3347659A1 (de) 1983-12-31 1985-07-11 Bayer Ag, 5090 Leverkusen Neue lackloesungen auf der basis von hydantoingruppen enthaltenden polymeren
US4664825A (en) 1984-10-25 1987-05-12 The Lubrizol Corporation Sulfurized compositions and lubricants containing them
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
AU634871B2 (en) 1990-03-20 1993-03-04 Banyu Pharmaceutical Co., Ltd. Substituted amine derivatives having anti-hyperlipemia activity
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
ATE135583T1 (de) 1991-06-18 1996-04-15 American Home Prod Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
CN1069492A (zh) * 1991-08-21 1993-03-03 山之内制药株式会社 4-酰胺基咪唑衍生物
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5352783A (en) 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5547948A (en) 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
CA2369303A1 (en) * 1999-04-14 2000-10-19 Arthur B. Pardee Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
CA2416976C (en) * 2000-08-11 2008-05-20 Wyeth Treatment of estrogen receptor positive carcinoma with a rapamycin and an antiestrogen
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.

Also Published As

Publication number Publication date
USRE41084E1 (en) 2010-01-19
BR0211769A (pt) 2004-07-27
NO20073801L (no) 2004-02-06
HK1061204A1 (en) 2004-09-10
EP1671943A1 (en) 2006-06-21
CY1104983T1 (el) 2010-03-03
JP2005505549A (ja) 2005-02-24
NO325503B1 (no) 2008-05-26
DE60208385T2 (de) 2006-08-03
CN1538842A (zh) 2004-10-20
NO20040558L (no) 2004-02-06
EP1414438B1 (en) 2005-12-28
AU2006233165A1 (en) 2006-11-09
IL159859A0 (en) 2004-06-20
ZA200401801B (en) 2005-06-06
DK1414438T3 (da) 2006-03-27
AR051778A2 (es) 2007-02-07
IL159859A (en) 2009-12-24
NZ560845A (en) 2008-09-26
CN1326523C (zh) 2007-07-18
CA2455126A1 (en) 2003-03-13
ES2252512T3 (es) 2006-05-16
WO2003020266A1 (en) 2003-03-13
TWI305527B (en) 2009-01-21
US20030050222A1 (en) 2003-03-13
PL368303A1 (en) 2005-03-21
JP2010155845A (ja) 2010-07-15
HUP0401089A3 (en) 2007-12-28
CN1803806A (zh) 2006-07-19
TW200626526A (en) 2006-08-01
KR20040029406A (ko) 2004-04-06
EA200501251A1 (ru) 2008-12-30
CN100415753C (zh) 2008-09-03
AU2006233165B2 (en) 2009-12-24
USRE40418E1 (en) 2008-07-01
SG170612A1 (en) 2011-05-30
EP1414438A1 (en) 2004-05-06
TWI300351B (en) 2008-09-01
AR036250A1 (es) 2004-08-25
US6617333B2 (en) 2003-09-09
NZ542272A (en) 2007-12-21
EA200400284A1 (ru) 2004-06-24
UA77200C2 (en) 2006-11-15
EA011098B1 (ru) 2008-12-30
ATE314069T1 (de) 2006-01-15
CN101279983A (zh) 2008-10-08
DE60208385D1 (de) 2006-02-02
USRE41253E1 (en) 2010-04-20
HUP0401089A2 (hu) 2004-09-28
EA006226B1 (ru) 2005-10-27
NZ530847A (en) 2006-02-24
AU2002330994B2 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
SG170612A1 (en) Antineoplastic combinations
SG148031A1 (en) Use of cci-779 as an antineoplastic agent
TW200503753A (en) Antineoplastic combinations
SG150559A1 (en) Antineoplastic combinations of cci-779 and rituximab
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
SG152906A1 (en) Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
HUP0400069A3 (en) Pharmaceutical combinations and their use in preventing and treating the thrombosis
ZA200306232B (en) Treatment involving DKK-1 or antagonists thereof.
SG153647A1 (en) Antineoplastic combinations
AR033012A1 (es) Combinaciones antineoplasicas
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
ECSP034866A (es) Combinaciones antineoplásticas
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
EG23929A (en) Isoxazolines derivatives and their use as antidepressants
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
AU2002234165A1 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
CA98963S (en) Leg for table
AU2001292500A1 (en) 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
AU2002364385A8 (en) Implantable device and the use thereof
GB0012250D0 (en) The treatment of intimal hyperplasia, and materials for use therein
WO2003030928A3 (en) Antitumor preparation
SI1392292T1 (sl) Piranoindazoli in njihova uporaba pri zdravljenjuglavkoma
GB0105742D0 (en) Complexes and their use
AU2002214441A1 (en) 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
GB0116969D0 (en) Neuro-phototransduction device and treatment

Legal Events

Date Code Title Description
FG Grant or registration